208 related articles for article (PubMed ID: 33926444)
1. Impact of China's zero mark-up drug policy on drug cost of NCDs' outpatients: an interrupted time series analysis.
Du J; Xie J; Qian Y; Wu M; Huang W; Yin J; Peng X; Deng D
BMC Health Serv Res; 2021 Apr; 21(1):404. PubMed ID: 33926444
[TBL] [Abstract][Full Text] [Related]
2. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.
Yan K; Yang C; Zhang H; Ye D; Liu S; Chang J; Jiang M; Zhao M; Fang Y
BMJ Open; 2020 Nov; 10(11):e037034. PubMed ID: 33243788
[TBL] [Abstract][Full Text] [Related]
3. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
Wang J; Li P; Wen J
BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
[TBL] [Abstract][Full Text] [Related]
4. The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis.
Wang R; Li X; Gu X; Cai Q; Wang Y; Yi ZM; Chen LC
Front Public Health; 2023; 11():1159119. PubMed ID: 37228740
[TBL] [Abstract][Full Text] [Related]
5. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
6. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
Qin Z; He M; Shen H; Liu S; Xu S; Chen L
Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
[TBL] [Abstract][Full Text] [Related]
7. Impacts of the zero mark-up policy on hospitalization expenses of T2DM and cholecystolithiasis inpatients in SC province, western China: an interrupted time series analysis.
Guo X; Xiao Y; Liu H; Li Q; Jiang Q; Liu C; Xie F; Wang H; Yang F; Han X; Yang H; Yang Y; Ye Y; Gan X; Long E
Front Public Health; 2023; 11():1079655. PubMed ID: 37188279
[TBL] [Abstract][Full Text] [Related]
8. The association between an increased reimbursement cap for chronic disease coverage and healthcare utilization in China: an interrupted time series study.
Shen M; He W; Yeoh EK; Wu Y
Health Policy Plan; 2020 Oct; 35(8):1029-1038. PubMed ID: 32869090
[TBL] [Abstract][Full Text] [Related]
9. "The biggest reform to China's health system": did the zero-markup drug policy achieve its goal at traditional Chinese medicines county hospitals?
Shi X; Zhu D; Man X; Wang W; Zhu K; Nicholas S; He P
Health Policy Plan; 2019 Sep; 34(7):483-491. PubMed ID: 31363744
[TBL] [Abstract][Full Text] [Related]
10. Effects of different mark-up drug policies on drug-related expenditures in tertiary public hospitals: an interrupted time series study in Shanghai, China, 2015-2018.
Wang X; Li F; Wang X; Zhang X; Liu C; Wang D; Wang H; Chen Y
Biosci Trends; 2020 Mar; 14(1):16-22. PubMed ID: 32092747
[TBL] [Abstract][Full Text] [Related]
11. Impacts of the Zero-Markup Drug Policy on Hospitalization Expenses of Patients with Stroke in Western China: An Interrupted Time Series Analysis.
Wu Y; Han X; Qiu J
Risk Manag Healthc Policy; 2024; 17():777-788. PubMed ID: 38584876
[TBL] [Abstract][Full Text] [Related]
12. The impact of zero markup drug policy on patients' healthcare utilization and expense: An interrupted time series study.
Zhu Z; Wang J; Sun Y; Zhang J; Han P; Yang L
Front Med (Lausanne); 2022; 9():928690. PubMed ID: 36457568
[TBL] [Abstract][Full Text] [Related]
13. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
Zhu D; Shi X; Nicholas S; Bai Q; He P
BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
[TBL] [Abstract][Full Text] [Related]
14. Impact of the zero-markup drug policy on hospitalisation expenditure in western rural China: an interrupted time series analysis.
Yang C; Shen Q; Cai W; Zhu W; Li Z; Wu L; Fang Y
Trop Med Int Health; 2017 Feb; 22(2):180-186. PubMed ID: 27865024
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of China's Zero Markup Drug Policy on provider-induced demand in secondary and tertiary hospitals.
Zhang X; Zimmerman A; Lai H; Zhang Y; Tang Z; Tang S; Ogbuoji O
Front Public Health; 2024; 12():1229722. PubMed ID: 38721544
[TBL] [Abstract][Full Text] [Related]
16. Will the zero-margin drug policy reduce the economic burden of stroke patients in China?
Fang Q; Shang D; Zhang Y; Geng X; Liu F; Zhang Q; Wang X
J Glob Health; 2021; 11():08007. PubMed ID: 34671464
[TBL] [Abstract][Full Text] [Related]
17. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
[TBL] [Abstract][Full Text] [Related]
18. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
19. The impact of the reference pricing policy in China on drug procurement and cost.
Jiang B; Zhou RJ; Feng XL
Health Policy Plan; 2022 Jan; 37(1):73-99. PubMed ID: 34379765
[TBL] [Abstract][Full Text] [Related]
20. [Economic burden and factors associated with Crohn's disease].
Zhou WP; Mu N; Jian WY; Wang HH
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 53(3):555-559. PubMed ID: 34145860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
